BusinessPROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMABy Nasdaq OMXMay 7, 2018, 12:01 PM UTC
BusinessPROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMABy Nasdaq OMXOct 18, 2017, 1:38 PM UTC
